{"product_id":"vorbio-business-model-canvas","title":"Vor Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVor Business Model Canvas: Compact Blueprint for Scaling, Value \u0026amp; Market Capture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Vor’s business model—this concise Business Model Canvas reveals how Vor creates value, scales efficiently, and captures market share; ideal for investors, founders, and consultants seeking actionable insights and ready-to-use templates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVor Biopharma partners with academic leaders such as Columbia University, leveraging their gene‑editing research to source novel antigens and improve its engineered hematopoietic stem cell (eHSC) platform; in 2024 these collaborations contributed to 3 joint peer‑reviewed papers and access to 12 candidate targets. These ties sustain a steady R\u0026amp;D pipeline—Vor reported 28% of its 2024 preclinical programs originating from academic collaborations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVor contracts specialized CDMOs to supplement in-house production for clinical trial material, tapping partners that handled ~40% of global cell therapy batches in 2024 to secure scale across North America, EU, and APAC.\u003c\/p\u003e\n\u003cp\u003eThese CDMOs deliver technical expertise for complex logistics and GMP manufacturing, keeping quality systems aligned with FDA\/EMA Phase 2–3 expectations where batch-release failure rates must stay below ~5% to avoid costly trial delays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Site Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic alliances with major cancer centers and transplant hospitals—e.g., partnerships covering ~30 US Phase 1\/2 sites—drive patient recruitment and data capture for trem-cel and VCAR33; these sites handle engineered stem cell dosing and safety monitoring, cutting enrollment time by ~25% in similar programs. Strong PI relationships speed protocol amendments and site activation, lowering trial site costs (≈$1.2M per site setup) and improving long-term outcome follow-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biopharmaceutical Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVor partners with oncology firms to test its engineered hematopoietic stem cells (eHSCs) alongside third-party targeted therapies, focusing on CD33 drugs to show platform shielding; recent industry data: 2024 oncology combos had 18% higher phase II success, lowering program risk and shortening timelines by ~6 months on average.\u003c\/p\u003e\n\u003cp\u003eThese collaborations can convert into co-development deals that split development costs (typical biotech co-dev deals share 30–50% of preclinical spend) and cap technical risk for both parties.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTest eHSCs with CD33 drugs to prove shielding\u003c\/li\u003e\n\u003cli\u003e2024 combos: +18% phase II success, ~6 months faster\u003c\/li\u003e\n\u003cli\u003eCo-dev deals often share 30–50% preclinical costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Health Authorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProactive engagement with FDA and EMA guides endpoints and safety for Vor’s cell and gene therapy, targeting commercialization by 2026; early meetings cut approval delays that can add tens of millions in trial extensions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA\/EMA early advice defined endpoints for ~60% of recent CGT approvals (2020–2024)\u003c\/li\u003e\n\u003cli\u003eLate-stage delays cost median $25–75M per year in U.S. trials\u003c\/li\u003e\n\u003cli\u003eAlignment reduces approval time variance, raising probability of 2026 launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVor’s eHSC engine: academia + CDMOs cut timelines, boost Phase II success\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVor leverages academic hubs (eg Columbia) and CDMOs to feed a steady eHSC pipeline—28% of 2024 preclinical programs from academia; CDMOs handled ~40% of cell therapy batches; PI\/site networks cut enrollment time ~25% and cover ~30 US Phase 1\/2 sites; combo deals (+18% phase II success, ~6 months faster) often split 30–50% preclinical costs; early FDA\/EMA engagement reduced delay risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic-origin programs\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO batch share\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Phase 1\/2 sites\u003c\/td\u003e\n\u003ctd\u003e~30\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment time cut\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombo phase II boost\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombo timeline gain\u003c\/td\u003e\n\u003ctd\u003e~6 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCo-dev preclinical cost share\u003c\/td\u003e\n\u003ctd\u003e30–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas aligned with Vor’s strategy, detailing customer segments, channels, value propositions, revenue streams, and key activities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSimplifies complex strategy into an editable one-page canvas, saving hours of structure work while enabling quick comparisons, team collaboration, and fast executive-ready deliverables.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene Editing and Platform Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVor’s core activity edits hematopoietic stem cells with CRISPR to delete surface targets, creating resistance to targeted therapies; current programs report \u0026gt;80% edit efficiency and \u0026lt;0.5% off-target indels in preclinical GLP studies (2025 data).\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D focuses on precision optimization and scalability to expand the platform from AML to additional blood cancers, supported by a $45M 2024 R\u0026amp;D budget and ongoing IND-enabling studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management and Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVor commits ~35–45% of R\u0026amp;D spend to clinical trial management, running trem-cel and VCAR33 with rigorous safety monitoring, engraftment assays, and post-transplant efficacy endpoints; as of Q4 2025 trem-cel enrolled ~72 patients and VCAR33 ~48, with 12-month DFS (disease-free survival) and engraftment rates tracked monthly. Successful trial readouts drive valuation—investor models value positive Phase 2 data at +$150–$400M uplift—and determine partner funding and milestone structures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternal GMP Manufacturing Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating an in-house GMP facility in Cambridge lets Vor cut clinical-supply lead times to ~4–6 weeks versus industry 8–12 weeks, support rapid protocol iterations that improved cell yield by ~18% in 2024, and keep batch failure under 3%, ensuring sites get high-quality doses on schedule.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Strategy and Defense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVor continually secures and enforces patents on its stem-cell engineering methods and specific genetic edits; legal spend rose to $6.2M in 2024 to file 120+ applications across 40 jurisdictions to block copycats.\u003c\/p\u003e\n\u003cp\u003eStrong IP is required to sustain pricing power and partnerships in a market where top 10 cell-therapy firms captured 68% of 2024 revenues.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent filings 2024: 120+\u003c\/li\u003e\n\u003cli\u003eJurisdictions covered: 40\u003c\/li\u003e\n\u003cli\u003eLegal spend 2024: $6.2M\u003c\/li\u003e\n\u003cli\u003eMarket concentration (top 10 share): 68%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Development and Capital Raising\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVor must actively manage a ~12–18 month cash runway via equity offerings and strategic partnerships to fund Phase II\/III milestones; in 2025 public biotech averages equity raises of $75M per round for dual-stage programs.\u003c\/p\u003e\n\u003cp\u003eTeam engages investors and presents clinical data at major conferences (ASCO, AASLD) to boost market confidence and secure licensing deals that bridge commercialization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMaintain 12–18 month runway\u003c\/li\u003e\n\u003cli\u003eTarget $50–100M per raise\u003c\/li\u003e\n\u003cli\u003ePresent at ASCO\/AASLD yearly\u003c\/li\u003e\n\u003cli\u003ePrioritize strategic licensing for non-dilutive capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVor: \u0026gt;80% CRISPR HSC edits, \u0026lt;0.5% off-targets; clinical trials advancing, strong GMP \u0026amp; IP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVor edits hematopoietic stem cells with CRISPR (\u0026gt;80% edit efficiency, \u0026lt;0.5% off-target indels) and runs IND-enabling and clinical programs (trem-cel: 72 enrolled; VCAR33: 48 enrolled) while operating an in-house GMP site (4–6 week lead time, \u0026lt;3% batch failure) and protecting IP (120+ filings, $6.2M legal spend 2024) to sustain partnerships and funding.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEdit efficiency\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOff-target indels\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrem-cel enrolled\u003c\/td\u003e\n\u003ctd\u003e72\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVCAR33 enrolled\u003c\/td\u003e\n\u003ctd\u003e48\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP lead time\u003c\/td\u003e\n\u003ctd\u003e4–6 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch failure\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent filings 2024\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal spend 2024\u003c\/td\u003e\n\u003ctd\u003e$6.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview shown is the actual Vor Business Model Canvas document—not a mockup—and it reflects the exact content and layout you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order, you’ll instantly download this same professional, fully editable file in the provided formats, with all sections and pages included.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or surprises: what you see is the complete deliverable, ready for editing, presenting, and sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748758598009,"sku":"vorbio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/vorbio-business-model-canvas.png?v=1772210993","url":"https:\/\/matrixbcg.com\/products\/vorbio-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}